Bicycle Therapeutics PLC (NAS:BCYC)
$ 21.71 0.35 (1.64%) Market Cap: 826.57 Mil Enterprise Value: 400.07 Mil PE Ratio: 0 PB Ratio: 2.31 GF Score: 70/100

Bicycle Therapeutics PLC at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 02:00PM GMT
Release Date Price: $24.42 (-2.24%)
Jeff Hung
Morgan Stanley - Analyst

Morning. Welcome to the Morgan Stanley Global Healthcare Conference. I'm Jeff Hung, one of the biotech analysts. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

For this session, we have Bicycle Therapeutics with CEO Kevin Lee; CFO Lee Kalowski; CSO Nick Keen; and CMO Dominic Smethurst. Welcome.

So for those who may not be familiar with Bicycle, can you provide a brief introduction?

Kevin Lee
Bicycle Therapeutics PLC - CEO

Hi, everyone. I'm Kevin Lee, CEO of Bicycle, and thanks to Jeff and the Morgan Stanley team for the invitation. Bicycles are actually small peptides, constrained peptides. So very different than what you would be probably used to. These are peptides typically 9 to 15 amino acids in length.

And what differentiates them

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot